Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Abbott quarterly profit rises 28.3% on strong sales of COVID-19 tests

10/21/2020 | 07:34am EST

Oct 21 (Reuters) - Abbott Laboratories posted a 28.3% rise in third-quarter profit on Wednesday, helped by strong sales of COVID-19 tests and strength in its nutrition and diabetes businesses.

The company's net earnings rose to $1.23 billion, or 69 cents per share, in the quarter ended Sept. 30, from $960 million, or 53 cents per share, a year earlier. (Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Arun Koyyur)


© Reuters 2020
All news about ABBOTT LABORATORIES
12/02ABBOTT LABORATORIES : FreeStyle Libre 2 Now Approved for Adults and Children wit..
AQ
11/20ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
11/19ABBOTT LABORATORIES : Becomes first anchor sponsor of american diabetes associat..
AQ
11/18ABBOTT LABORATORIES : Launches the first infant formula in canada with an ingred..
AQ
11/17ABBOTT LABORATORIES : Launches the First Infant Formula in Canada with an Ingred..
AQ
11/17ABBOTT LABORATORIES : Named industry sustainability leader for the eighth year i..
AQ
11/16HHS Official Says The Agency Has Responded To Every State That Has Requested ..
RE
11/16ABBOTT : Named Industry Sustainability Leader for the Eighth Year in a Row on th..
PR
11/12ABBOTT LABORATORIES : Entry into a Material Definitive Agreement, Termination of..
AQ
11/12ABBVIE : Vice Chairman, Chief Commercial Officer Carlos Alban to Retire
DJ
More news
Financials (USD)
Sales 2020 33 873 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 44,0x
Yield 2020 1,34%
Capitalization 185 B 185 B -
EV / Sales 2020 5,81x
EV / Sales 2021 5,05x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 118,44 $
Last Close Price 107,90 $
Spread / Highest target 20,5%
Spread / Average Target 9,77%
Spread / Lowest Target -24,0%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES24.22%184 876
MEDTRONIC PLC0.35%150 831
BECTON, DICKINSON AND COMPANY-10.74%69 175
HOYA CORPORATION23.88%46 806
ALIGN TECHNOLOGY, INC.86.97%40 293
BAXTER INTERNATIONAL INC.-6.72%38 986